Core Viewpoint - Moderna's mNexspike vaccine has received a positive opinion from the EMA's CHMP, recommending EU approval for its next-generation refrigerator-stable COVID-19 vaccine aimed at individuals aged 12 and older [1][6]. Group 1: Product Approval and Market Strategy - A final decision from the European Commission regarding mNexspike is anticipated soon, with plans for distribution across Europe following regulatory timelines [2]. - mNexspike is Moderna's third product to receive a positive CHMP opinion, joining Spikevax and mResvia, indicating a growing portfolio in the vaccine market [3]. - The approval of mNexspike could enhance Moderna's growth outlook by strengthening its respiratory franchise and generating incremental revenues in the EU starting in 2026-2027 [8]. Group 2: Efficacy and Safety Data - The positive opinion for mNexspike is based on a phase III study with approximately 11,400 participants, demonstrating non-inferior vaccine efficacy compared to Spikevax, with a 9.3% higher relative vaccine efficacy overall and 13.5% higher in adults aged 65 and older [4][6]. - Safety profiles for mNexspike are comparable to Spikevax, showing fewer local reactions and similar rates of systemic adverse events, with common side effects including injection-site pain, fatigue, headache, and myalgia [5][6]. Group 3: Market Context and Demand - COVID-19 remains prevalent in the EU, with ongoing demand for updated vaccines, particularly for high-risk populations such as the elderly, due to waning immunity and the emergence of new variants [9]. - mNexspike offers improved shelf life and storage benefits, which are crucial for distribution in areas with limited cold-chain infrastructure [11].

For the first time in three decades, the American Academy of Pediatrics is breaking from the federal government's recommendations over CO 19. The group is strongly advising the vaccine for kids between the ages of 6 months and 2 years old as well as older immunompromised children. That contradicts new CDC guidance which does not recommend shots for healthy children at any. ...

Core Insights - Novavax announced positive results from a late-stage study of its COVID-19-influenza combination (CIC) and standalone influenza vaccine candidates, showing robust immune responses in adults aged 65 and older [1][2][8] - The study's findings will guide the design of another late-stage trial that could support regulatory submissions if successful [3][8] - Novavax is seeking strategic collaborations to finance further development and commercialization of both vaccine candidates as part of a strategic shift to expand its pipeline [4][8] Stock Performance - Novavax shares have underperformed the industry year to date [5] Recent Developments - The announcement followed the FDA's approval of Nuvaxovid for older adults, with a narrower label than expected, restricting use in individuals aged 12-64 with high-risk conditions [7][8] - Sanofi has acquired exclusive global marketing rights for Nuvaxovid, part of a multi-billion-dollar deal, and will receive tiered royalties on future sales [10] Competitive Landscape - Other companies like Pfizer and Moderna are also developing COVID-flu combination vaccines, with Moderna ahead in its investigational candidate mRNA-1083, despite a recent setback [11][12] - Pfizer faced challenges in its phase III study for its combination vaccine, missing one of its primary immunogenicity objectives [13] - Sanofi is testing multiple COVID-19/flu combination vaccine candidates, with two receiving fast-track designation from the FDA [14]